Speed to Market Biorasi positions itself as a speed-driven CRO for small to mid-sized biotech and biopharma sponsors, offering speed-to-market strategies across dermatology, oncology, neurology, nephrology and other therapeutic areas. With a track record that includes five FDA-approved trials in seven years, multiple study rescues, and repeat sponsor engagements, the company demonstrates reliability, flexibility, and proven delivery. Its full service and standalone solutions can be tailored to tight timelines and evolving trial demands, making it a compelling partner for sponsors pursuing rapid, predictable execution.

AI Enabled Trials Biorasi has formed a strategic partnership with Ryght AI to enhance site activation and optimization using AI driven digital twins for every research site. This positions the CRO to offer AI enabled trial capabilities such as optimized site selection, faster activations, and predictive analytics for trial performance, which can reduce cycle times and improve data quality for sponsors pursuing digital trial transformations.

Leadership Governance Recent leadership appointments signal a strengthened management layer and strategic governance: Melissa Alesse appointed COO in January 2026 and Chris O'Brien joining the Board of Directors in March 2026, complemented by Kristen K Buck as Scientific Medical Advisor in 2023. This depth supports scalable delivery, client confidence, and long term partnerships.

Global Sector Focus The company focuses on dermatology, oncology, neurology, nephrology and other key therapeutic areas, serving sponsors globally from its base in Florida with a workforce of 51-200. The combination of therapeutic breadth, global reach, and a strong track record of repeat business and FDA level outcomes supports cross-border trials and expansion for mid-sized sponsors seeking diverse trial portfolios.

Partnership Track Record Biorasi has demonstrated a capability to grow sponsor relationships through targeted partnerships and expansions outside the US, including collaborations such as Alzamend Neuro (2023) and Citius Pharmaceuticals (2022), and more recently the Ryght AI partnership (2025). The launch of a dedicated sponsor focused website in 2025 further signals ongoing sales and marketing investments to attract new mid-size biotech and biopharma clients.